Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis.

J Clin Med · 2026 · PMC12842056 · PMID 41598379

Europe PMC DOI

hedged sentences

0.0780

closest p · 1.6× alpha

0.0780

boldest claim

The sentences

showed a trendp = 0.078so close (0.05 < p ≤ 0.1)

SIRI showed a trend towards reduction over time ( p = 0.078), which did not reach conventional statistical significance, and should therefore be interpreted cautiously.

also in 53,322 other papers

an overall trendno p-value reported

Discussion In this real-world study, we investigated the long-term trajectory of systemic inflammatory indices in patients with moderate-to-severe plaque psoriasis treated with guselkumab over a period of up to 156 weeks, observing an overall trend toward reduction in several markers—particularly PLR, MLR, and SIRI—supporting the hypothesis that IL-23 inhibition exerts sustained systemic anti-inflammatory effects.

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.